In October 2006, Genaco Biomedical Products Inc was acquired by the Dutch firm QIAGEN. Genaco Biomedical Products Inc products include commercial kits for prenatal screening and diagnosis of common genetic diseases. Genaco Biomedical Products, Inc (Genaco), is a post-genomic era biotechnology platform company, utilizing the information and technologies derived from the human genome project (HGP) for developing molecular differential diagnostics (MDD). The company's mission is to integrate high throughput technologies and develop molecular diagnostics that can guide the treatment of infectious diseases, cancer, and other diseases. Genaco currently provides diagnostics technologies for rapid and accurate identification of disease. Genaco is an innovator in the development of multiplex diagnostic assays through the incorporation of our proprietary technologies with the Luminex xMAP platform. Technologies Tem-PCR (Target-enriched multiplex PCR) and ROCASH (Reporter Oligo Capture after Specific Hybridization) are two unique technologies developed by Genaco scientists. Tem-PCR is a method for specific amplification of multiple nucleotide targets in a single assay system. ROCASH is a high-throughput method for specific detection of multiple single-base mutations. The firm uses Luminex's xMAP technology (Luminex Corporation, Austin, Texas) as our platform for the development of multiplex diagnostic assays. Instead of studying thousands of genes like other high throughput technologies, the xMAP studies only 100 at a time. While the xMAP's screening capability is not as vast, this array method is more reliable and because of the high reproducibility, it is the only FDA approved high throughput platform.
